Journal of Molecular and Cellular Cardiology
Volume 44, Issue 3 , Pages 527-538 , March 2008

TGF-β1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60c-src/EGFRY845 and Rho/ROCK signaling

Received 11 October 2007 ,Revised 4 December 2007 ,Accepted 11 December 2007.

References 

  1. Kutz SM, Hordines J, McKeown-Longo PJ, Higgins PJ. TGF-β1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J. Cell Sci. 2001;114:3905–3914
  2. Yue J, Mulder KM. Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol. Ther. 2001;91:1–34
  3. Bottinger EP, Bitzer M. TGF-β signaling in renal disease. J. Am. Soc. Nephrol. 2002;13:2600–2610
  4. Bhowmick NA, Ghiassi M, Aakre M, Brown K, Singh V, Moses HL. TGF-β-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc. Natl. Acad. Sci. U. S. A. 2003;100:15548–15553
  5. Derynck R, Zhang Y. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature. 2003;425:577–584
  6. Ten Dijke P, Hill CS. New insights into TGF-β-Smad signalling. Trends Biochem. Sci. 2004;29:265–273
  7. Moustakas A, Heldin CH. Non-Smad TGF-β signals. J. Cell Sci. 2005;118:3573–3584
  8. Allen RR, Higgins PJ. Plasminogen activator inhibitor type-1 expression and the pathophysiology of TGF-β1-induced epithelial-to-mesenchymal transition. Recent Res. Devel. Physiol. 2004;2:355–366
  9. Wilkins-Port CE, Higgins PJ. Regulation of extracellular matrix remodeling following transforming growth factor-β1/epidermal growth factor-stimulated epithelial–mesenchymal transition in human premalignant keratinocytes. Cells Tissues Organs. 2007;185:116–122
  10. Petzelbauer E, Springhorn JP, Tucker AM, Madri JA. Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF-β1. Am. J. Pathol. 1996;149:923–931
  11. DeYoung MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation. 2001;104:1972–1977
  12. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 2001;104:839–844
  13. Vaughan DE. PAI-1 and cellular migration: dabbling in paradox. Arterioscler. Thromb. Vasc. Biol. 2002;22:1522–1523
  14. Vaughan DE. PAI-1 and TGF-β: unmasking the real driver of TGF-β-induced vascular pathology. Arterioscler. Thromb. Vasc. Biol. 2006;26:679–680
  15. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003;23:1979–1989
  16. Eddy AA, Fogo A. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 2006;17:2999–3012
  17. Singh NN, Ramji DP. The role of transforming growth factor-β in atherosclerosis. Cytokine Growth Factor Rev. 2006;17:487–499
  18. Otsuka G, Agah R, Frutkin AD, Wight TN, Dichek DA. Transforming growth factor β1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler. Thromb. Vasc. Biol. 2006;26:737–743
  19. Otsuka G, Stempien-Otero A, Frutkin AD, Dichek DA. Mechanisms of TGF-b1-induced intimal growth. Plasminogen-independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. Cir Res. 2007;100:1300–1307
  20. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 2006;355:2631–2639
  21. Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler. Thromb. Vasc. Biol. 2005;25:365–371
  22. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 2005;25:1767–1775
  23. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 2006;98:322–334
  24. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101:2030–2033
  25. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, et al. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/− haploinsufficient mice. Circulation. 2005;112:2959–2965
  26. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler. Thromb. Vasc. Biol. 2001;21:868–873
  27. Nakakuki T, Ito M, Iwasaki H, Kureishi Y, Okamoto R, Moriki N, et al. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2005;25:2088–2093
  28. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation. 2005;111:3261–3268
  29. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-β. Proc. Natl. Acad. Sci. U. S. A. 2001;98:6686–6691
  30. Guo B, Inoki K, Isono M, Mori H, Kanasaki K, Sugimoto T, et al. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-β in rat mesangial cells. Kidney Int. 2005;68:972–984
  31. Samarakoon R, Higgins CE, Higgins SP, Kutz SM, Higgins PJ. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-β1-stimulated smooth muscle cells is pp60c-src/MEK-dependent. J. Cell Physiol. 2005;204:236–246
  32. Kutz SM, Higgins CE, Samarakoon R, Higgins SP, Allen RR, Qi L, et al. TGF-β1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling. Exp. Cell Res. 2006;312:1093–1105
  33. Woodward RN, Finn AV, Dichek DA. Identification of intracellular pathways through which TGF-β1 upregulates PAI-1 expression in endothelial cells. Atherosclerosis. 2006;186:92–100
  34. Samarakoon R, Higgins PJ. MEK/ERK pathway mediates cell-shape-dependent plasminogen activator inhibitor type 1 gene expression upon drug-induced disruption of the microfilament and microtubule networks. J. Cell Sci. 2002;115:3093–3103
  35. Chen S, Crawford M, Day RM, Briones VR, Leader JE, Jose PA, et al. RhoA modulates Smad signaling during transforming growth factor-β-induced smooth muscle differentiation. J. Biol. Chem. 2006;281:1765–1770
  36. Kita T, Hata Y, Kano K, Miura M, Nakao S, Noda Y, et al. Transforming growth factor-β2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes. 2007;56:231–238
  37. Loirand G, Guilluy C, Pacaud P. Regulation of Rho proteins by phosphorylation in the cardiovascular system. Trends in Cardiovascular Med. 2006;16(6):199–204
  38. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998;17:3091–3100
  39. Hua X, Liu X, Ansari DO, Lodish HF. Synergistic cooperation of TFE3 and smad proteins in TGF-β-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev. 1998;12:3084–3095
  40. Levy L, Hill CS. Smad4 dependency defines two classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial–mesenchymal transition from its antiproliferative and migratory responses. Mol. Cell. Biol. 2005;25:8108–8125
  41. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 1999;274:8335–8343
  42. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 2004;84:767–801
  43. Itoh S, ten Dijke P. Negative regulation of TGF-β receptor/Smad signal transduction. Curr. Opin. Cell Biol. 2007;19:176–118
  44. Allen RR, Qi L, Higgins PJ. Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes. J. Cell. Physiol. 2005;203:156–165
  45. Higgins PJ. TGF-β1-stimulated p21ras-ERK signaling regulates expression of the angiogenic SERPIN PAI-1. Recent Res. Develop. Biochem. 2006;7:31–45
  46. Qi L, Allen RR, Lu Q, Higgins CE, Garone R, Staiano-Coico L, et al. PAI-1 transcriptional regulation during the G0→G1 transition in human epidermal keratinocytes. J. Cell. Biochem. 2006;99:495–507
  47. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 2001;60:587–596
  48. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen t, Ginsburg D, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 1996;97:232–237
  49. Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation. 2001;103:3105–3110
  50. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler. Thromb. Vasc. Biol. 2006;26:2200–2207
  51. Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 2002;106:491–496
  52. Jones PA, Scott-Burden T, Gevers W. Glycoprotein, elastin, and collagen secretion by rat smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A. 1979;76:353–357

PII: S0022-2828(07)01349-1

doi: 10.1016/j.yjmcc.2007.12.006

Journal of Molecular and Cellular Cardiology
Volume 44, Issue 3 , Pages 527-538 , March 2008

Article Tools

* Image Usage & Resolution